Treatment of the inflammatory myopathies: update and practical recommendations
Gerald J. D. Hengstman, Frank H J van den Hoogen, Baziel G.M. van Engelen
Abstract
Gerald J. D. Hengstman, Frank H J van den Hoogen, Baziel G.M. van Engelen
Abstract
BACKGROUND: The inflammatory myopathies are a heterogeneous group of diseases including dermatomyositis, polymyositis, and inclusion body myositis. Clinical trials in myositis are rare, making it difficult to make clear recommendations on the treatment of these rare disorders. OBJECTIVE: To give an overview of treatment options and strategies and to provide the clinician with a framework that can be used in treating patients with myositis. METHODS: Results of clinical trials in myositis, case series and important case reports are presented and discussed. RESULTS/CONCLUSION: Most patients with dermatomyositis or polymyositis require treatment with oral high-dose prednisone combined with azathioprine or methotrexate to facilitate early tapering of prednisone. In case of treatment failure, intravenous immunoglobulin can be tried, followed by rituximab, mycophenolate mofetil, or tacrolimus depending on the specific clinical situation. A treatment trial with oral prednisone combined with methotrexate is advised in a subgroup of patients with inclusion body myositis.
OpenAlex reports 59 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
BACKGROUND: The inflammatory myopathies are a heterogeneous group of diseases including dermatomyositis, polymyositis, and inclusion body myositis. Clinical trials in myositis are rare, making it difficult to make clear recommendations on the treatment of these rare disorders. OBJECTIVE: To give an overview of treatment options and strategies and to provide the clinician with a framework that can be used in treating patients with myositis. METHODS: Results of clinical trials in myositis, case series and important case reports are presented and discussed. RESULTS/CONCLUSION: Most patients with dermatomyositis or polymyositis require treatment with oral high-dose prednisone combined with azathioprine or methotrexate to facilitate early tapering of prednisone. In case of treatment failure, intravenous immunoglobulin can be tried, followed by rituximab, mycophenolate mofetil, or tacrolimus depending on the specific clinical situation. A treatment trial with oral prednisone combined with methotrexate is advised in a subgroup of patients with inclusion body myositis.
Key concepts: Medicine, Polymyositis, Dermatomyositis, Inclusion body myositis, Myositis, Rituximab, Azathioprine, Prednisone